-
公开(公告)号：US09156899B2
公开(公告)日：2015-10-13
申请号：US14032963
申请日：2013-09-20
申请人： Ambrx, Inc , Eli Lilly and Company
发明人： Feng Tian , Anna-Maria A. Hays Putnam , Frank Song , Stephanie Chu , Joseph Sheffer , Richard S. Barnett , Marc Siladi , Kyle Atkinson , Darin Lee , Peter C. Canning
IPC分类号： C07K14/505 , C12N15/10 , A61K38/00
CPC分类号： C07K14/505 , A61K38/00 , A61K38/1816 , A61K47/60 , C12N15/102
摘要： Modified animal erythropoietin polypeptides and uses thereof are provided.
摘要翻译： 提供了改良的动物促红细胞生成素多肽及其用途。
-
公开(公告)号：US09644014B2
公开(公告)日：2017-05-09
申请号：US14854819
申请日：2015-09-15
申请人： Ambrx, Inc. , Eli Lilly and Company
发明人： Feng Tian , Anna-Maria A. Hays Putnam , Frank Song , Stephanie Chu , Joseph Sheffer , Richard S. Barnett , Marc Siladi , Kyle Atkinson , Darin Lee , Peter C. Canning
IPC分类号： A61K38/00 , A61K38/18 , C07K14/505 , C12N15/10 , A61K47/48
CPC分类号： C07K14/505 , A61K38/00 , A61K38/1816 , A61K47/60 , C12N15/102
摘要： Modified animal erythropoietin polypeptides and uses thereof are provided.
-
3.发明申请Compositions Containing, Methods Involving, and Uses of Non-Natural Amino Acid Linked Dolastatin Derivatives 审中-公开含有非天然氨基酸相关多拉司他汀衍生物的组合物，涉及方法和用途公开(公告)号：US20150080559A1
公开(公告)日：2015-03-19
申请号：US14122667
申请日：2012-05-24
申请人： AMBRX, INC.
发明人： Zhenwei Miao , Kyle Atkinson , Sandra Biroc , Timothy Buss , Melissa Neal , Vadim Kraynov , Robin Mardsen , Jason Pinkstaff , Lillian Skidmore , Ying Sun , Agnieszka Szydlik , Ianina Valenta
CPC分类号： C07K5/06 , A61K31/337 , A61K31/427 , A61K39/39558 , A61K47/6803 , A61K47/6855 , A61K2039/505 , C07D207/325 , C07D401/12 , C07D417/12 , C07K5/02 , C07K16/2896 , C07K2317/24 , C07K2317/76 , A61K2300/00
摘要： Disclosed herein are non-natural amino acids and dolastatin analogs that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The dolastatin analogs can include a wide range of possible functionalities, but typically have at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Also disclosed herein are non-natural amino acid dolastatin analogs that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such dolastatin analogs. Typically, the modified dolastatin analogs include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid dolastatin analogs and modified non-natural amino acid dolastatin analogs, including therapeutic, diagnostic, and other biotechnology uses.
摘要翻译： 本文公开了包含至少一种非天然氨基酸的非天然氨基酸和多拉斯达汀类似物，以及用于制备这种非天然氨基酸和多肽的方法。 多拉司他汀类似物可以包括广泛的可能功能，但通常具有至少一个肟，羰基，二羰基和/或羟胺基团。 本文还公开了在翻译后进一步修饰的非天然氨基酸多拉司他汀类似物，用于实现这种修饰的方法，以及纯化这种多拉司他汀类似物的方法。 通常，修饰的多拉司他汀类似物包括至少一个肟，羰基，二羰基和/或羟胺基团。 进一步披露的是使用这种非天然氨基酸多拉司他汀类似物和经修饰的非天然氨基酸多拉司他丁类似物的方法，包括治疗，诊断和其他生物技术用途。
-
公开(公告)号：US11420999B2
公开(公告)日：2022-08-23
申请号：US17142169
申请日：2021-01-05
申请人： Ambrx, Inc.
发明人： Zhenwei Miao , Kyle Atkinson , Sandra Biroc , Timothy Buss , Melissa Neal , Vadim Kraynov , Robin Marsden , Jason Pinkstaff , Lillian Skidmore , Ying Sun , Agnieszka Szydlik , Delia Ianina Lopez De Valenta
IPC分类号： C07K5/10 , C07K5/103 , C07D207/08 , C07D401/12 , C07D417/12 , C07K5/02 , A61K47/68 , A61K38/07 , C07K5/062
摘要： Disclosed herein are non-natural amino acids and dolastatin analogs that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The dolastatin analogs can include a wide range of possible functionalities, but typically have at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Also disclosed herein are non-natural amino acid dolastatin analogs that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such dolastatin analogs. Typically, the modified dolastatin analogs include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid dolastatin analogs and modified non-natural amino acid dolastatin analogs, including therapeutic, diagnostic, and other biotechnology use.
-
5.发明申请公开(公告)号：US20180009845A1
公开(公告)日：2018-01-11
申请号：US15702682
申请日：2017-09-12
申请人： Ambrx, Inc.
发明人： Zhenwei Maio , Kyle Atkinson , Sandra Biroc , Timothy Buss , Melissa Neal , Vadim Kraynov , Robin Marsden , Jaosn Pinkstaff , Lillian Skidmore , Ying Sun , Agnieszka Szydlik , Delia Lanina Lopez De Valenta
IPC分类号： C07K5/103 , C07K5/02 , C07D401/12 , C07D207/08 , A61K38/07 , C07D417/12 , C07K5/062
CPC分类号： C07K5/101 , A61K38/07 , A61K47/6803 , A61K47/6817 , A61K47/6849 , A61K47/6855 , A61K47/6861 , C07D207/08 , C07D401/12 , C07D417/12 , C07K5/0205 , C07K5/06043
摘要： Disclosed herein are non-natural amino acids and dolastatin analogs that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The dolastatin analogs can include a wide range of possible functionalities, but typically have at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Also disclosed herein are non-natural amino acid dolastatin analogs that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such dolastatin analogs. Typically, the modified dolastatin analogs include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid dolastatin analogs and modified non-natural amino acid dolastatin analogs, including therapeutic, diagnostic, and other biotechnology use.
-
公开(公告)号：US10954270B2
公开(公告)日：2021-03-23
申请号：US15702682
申请日：2017-09-12
申请人： Ambrx, Inc.
发明人： Zhenwei Miao , Kyle Atkinson , Sandra Biroc , Timothy Buss , Melissa Neal , Vadim Kraynov , Robin Marsden , Jason Pinkstaff , Lillian Skidmore , Ying Sun , Agnieszka Szydlik , Delia Ianina Lopez De Valenta
IPC分类号： C07K5/00 , C07K5/103 , C07D207/08 , C07D401/12 , C07D417/12 , C07K5/02 , A61K47/68 , A61K38/07 , C07K5/062
摘要： Disclosed herein are non-natural amino acids and dolastatin analogs that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The dolastatin analogs can include a wide range of possible functionalities, but typically have at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Also disclosed herein are non-natural amino acid dolastatin analogs that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such dolastatin analogs. Typically, the modified dolastatin analogs include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid dolastatin analogs and modified non-natural amino acid dolastatin analogs, including therapeutic, diagnostic, and other biotechnology use.
-
7.发明申请Compositions Containing, Methods Involving, and Uses of Non-Natural Amino Acid Linked Dolastatin Derivatives 有权含有非天然氨基酸相关多拉司他汀衍生物的组合物，涉及方法和用途公开(公告)号：US20160052966A1
公开(公告)日：2016-02-25
申请号：US14122672
申请日：2012-05-24
申请人： AMBRX, INC.
发明人： Zhenwei Miao , Kyle Atkinson , Sandra Biroc , Timothy Buss , Melissa Neal , Vadim Kraynov , Robin Marsden , Jason Pinkstaff , Lillian Skidmore , Ying Sun
CPC分类号： C07K5/101 , A61K38/07 , A61K47/6803 , A61K47/6817 , A61K47/6849 , A61K47/6855 , A61K47/6861 , C07D207/08 , C07D401/12 , C07D417/12 , C07K5/0205 , C07K5/06043
摘要： Disclosed herein are non-natural amino acids and dolastatin analogs that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The dolastatin analogs can include a wide range of possible functionalities, but typically have at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Also disclosed herein are non-natural amino acid dolastatin analogs that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such dolastatin analogs. Typically, the modified dolastatin analogs include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid dolastatin analogs and modified non-natural amino acid dolastatin analogs, including therapeutic, diagnostic, and other biotechnology use.
摘要翻译： 本文公开了包含至少一种非天然氨基酸的非天然氨基酸和多拉斯达汀类似物，以及用于制备这种非天然氨基酸和多肽的方法。 多拉司他汀类似物可以包括广泛的可能功能，但通常具有至少一个肟，羰基，二羰基和/或羟胺基团。 本文还公开了在翻译后进一步修饰的非天然氨基酸多拉司他汀类似物，用于实现这种修饰的方法，以及纯化这种多拉司他汀类似物的方法。 通常，修饰的多拉司他汀类似物包括至少一个肟，羰基，二羰基和/或羟胺基团。 进一步公开的是使用这种非天然氨基酸多拉司他汀类似物和修饰的非天然氨基酸多拉司他汀类似物的方法，包括治疗，诊断和其他生物技术用途。
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.033 秒)